General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-13 | 2024-09 | 0.13 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.08 | 0.13 | 0.05 | 62.50% |
2024-05-09 | 2024-03 | 0.05 | 0.08 | 0.03 | 60.00% |
2024-02-28 | 2023-12 | 0.02 | 0.04 | 0.02 | 100.00% |
2023-11-08 | 2023-09 | -0.01 | 0.01 | 0.02 | 200.00% |
2023-08-09 | 2023-06 | -0.02 | -0.02 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-09 | Raymond James | Upgrade | Strong Buy | Strong Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-26 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-07 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-02 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-18 | ELMS STEVEN A | Director | 0.00 | Sale |
2024-02-25 | FINGER ALISON CECILY | Director | 24.04K | Stock Award(Grant) |
2024-02-25 | FONG BRYANT E. | Director | 83.94K | Stock Award(Grant) |
2024-08-26 | GROSSMAN ADAM S | Chief Executive Officer | 3.78M | Sale |
2024-08-28 | GROSSMAN JERROLD B | Director | 560.01K | Sale |
2024-09-08 | GUIHEEN LAWRENCE P | Director | 154.94K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 16.37M | 60.39M | 7.28% |
2023-06-29 | Vanguard Group Inc | 12.45M | 45.92M | 5.53% |
2023-06-29 | Perceptive Advisors Llc | 11.90M | 43.91M | 5.29% |
2023-06-29 | State Street Corporation | 10.51M | 38.80M | 4.67% |
2023-06-29 | Stonepine Capital Management, LLC | 8.79M | 32.45M | 3.91% |
2023-06-29 | Nuveen Asset Management, LLC | 8.56M | 31.58M | 3.81% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 6.41M | 23.66M | 2.85% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.05M | 23.30M | 2.69% |
2023-08-30 | iShares Russell 2000 ETF | 4.77M | 18.35M | 2.12% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.90M | 10.70M | 1.29% |
2023-06-29 | Invesco Main Street Small Cap Fund | 2.57M | 9.49M | 1.14% |
2023-06-29 | College Retirement Equities Fund-Stock Account | 2.08M | 7.68M | 0.93% |
I am an ADMA long hauler. It is inevitable that the rapid rise in revenue will translate into improved shareholder value. Almost 100% rise in annual revenue and multiple FDA approvals are bullish indicators.
$ADMA Preliminary Fourth Quarter and Full Year 2021 Revenues and 2022 Strategic Outlook should be available soon.
$ADMA ADMA Biologics should be announcing preliminary fourth quarter and full year 2021 revenues sometime this month. It could be a positive catalyst.
$ADMA has estimated revenue between $20 million and $20.5 million in Q3. Explosive revenue growth.
$ADMA I think Q3 report next month will show at least $20 million in revenue.
$ADMA This stock will reward those with patience. Penny stock company with a high demand product and explosive revenue growth is a setup for a massive short squeeze. Just wait for the catalyst.
$ADMA I have been trading ADMA stock since April 2020 and have made money every trade by buying on the big dips and selling on the spikes. I last sold at $2.60 and bought back at $1.95. Yes I’ve been holding the bag the last few months but ADMA has a history of volatility and the next round of upside volatility is coming. Waiting for a catalyst. This is a good rapidly growing company that sells a product that is in short supply and in high demand. A catalyst will come.
$ADMA We need a blowout 3Q report to get out of the quagmire but I’m patient.
$ADMA Nuveen Asset Management LLC grew its holdings in ADMA Biologics by 2,530.6% in the first quarter. Nuveen Asset Management LLC now owns 6,758,962 shares of the biotechnology company’s stock valued at $11,895,000 after purchasing an additional 6,502,025 shares during the period. Morgan Stanley boosted its stake in ADMA Biologics, Inc. by 85.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 380,576 shares of the biotechnology company’s stock after purchasing an additional 174,852 shares during the quarter.
$ADMA Last quarter ADMA reported $17.83 million in revenue, a 129% increase year over year. The FDA approvals are coming ahead of schedule. All the seeds that the company has planted are only beginning to bloom. Patient Stockholders will be rewarded handsomely very soon.
$ADMA Adam Grossman will be presenting today at the Morgan Stanley 19th Annual Global Healthcare Conference at 12:30pm. This is the link for the webcast.
https://www.admabiologics.com/investors/events-and-webcasts/detail/3178/morgan-stanley-19th-annual-global-healthcare-conference
$ADMA it is possible that institutional investors are unloading more shares. If it goes under a dollar I’ll buy more. The fundamentals of this company are still good. Multiple FDA approvals and massive revenue growth.
Let us at least $5 on it
$ADMA If this tanks to under $1.00 tomorrow I might buy more and average down. This is so far into oversold territory it’s ridiculous.
$ADMA Grossman needs to cutback on his $2 million yearly salary as a sign of support for the investors that are watching their investment diluted. He also needs to buy more shares. Why no insider buying at these levels?
$ADMA important contacts. We need answers.
COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552| sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
$ADMA All we can do as investors is to wait. In consideration of the stock market record high performance it difficult to be in an individual stock that keeps tanking, but ADMA is achieving its goals with many FDA approvals and skyrocketing revenue and we will be all reaping the rewards of our patience soon.
$ADMA
Perhaps the most bullish point comes from the company’s outlook and expectations. The company has a $100M revenue target exiting for this year and a goal of hitting “$300M or more with significant profitability beginning no later than the first quarter of 2024.”
In addition, the company reinforced that they are “considering alternative business opportunities to maximize stockholder value, including, for example, the acquisition or sale of specific assets or businesses, collaboration and or license agreements, or other co-development agreements or arrangements.”
https://seekingalpha.com/article/4449433-adma-biologics-feeling-bullish-after-encouraging-q2-earnings-report?_gl=11gyacgx_ga*UHJqVzEwYnRrZ1FUTGxkbHVZa0dXSDdZQVFjZXRQalVJR3g2aGgtamVqRVBaWlUxaGFVZ3FKUkNRVG1XTXR6dA..